Robert Bradsher
Concepts (296)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Blastomycosis | 36 | 2014 | 62 | 3.880 |
Why?
| Histoplasmosis | 12 | 2014 | 50 | 1.570 |
Why?
| Antifungal Agents | 19 | 2020 | 339 | 1.520 |
Why?
| Blastomyces | 17 | 2011 | 31 | 1.520 |
Why?
| Lung Diseases, Fungal | 16 | 2008 | 31 | 1.110 |
Why?
| Endemic Diseases | 3 | 2014 | 22 | 0.600 |
Why?
| Babesiosis | 1 | 2017 | 6 | 0.590 |
Why?
| Antigens, Fungal | 7 | 2011 | 24 | 0.590 |
Why?
| Mycoses | 6 | 2020 | 157 | 0.580 |
Why?
| Amphotericin B | 11 | 2010 | 110 | 0.570 |
Why?
| Blood Transfusion | 1 | 2017 | 121 | 0.540 |
Why?
| Cecal Diseases | 1 | 2014 | 7 | 0.480 |
Why?
| Colonic Diseases | 1 | 2014 | 14 | 0.470 |
Why?
| Adrenal Insufficiency | 1 | 2014 | 18 | 0.470 |
Why?
| Ulcer | 1 | 2014 | 22 | 0.470 |
Why?
| Azoles | 2 | 2010 | 28 | 0.360 |
Why?
| Central Nervous System Fungal Infections | 1 | 2010 | 3 | 0.360 |
Why?
| Ixodes | 1 | 2010 | 6 | 0.360 |
Why?
| Humans | 73 | 2020 | 49974 | 0.350 |
Why?
| Lyme Disease | 1 | 2010 | 32 | 0.350 |
Why?
| Borrelia burgdorferi | 1 | 2010 | 31 | 0.350 |
Why?
| HIV Infections | 1 | 2011 | 357 | 0.280 |
Why?
| Dermatomycoses | 4 | 1997 | 19 | 0.260 |
Why?
| Male | 40 | 2017 | 25241 | 0.260 |
Why?
| Doxycycline | 3 | 2017 | 32 | 0.250 |
Why?
| Histoplasma | 6 | 2011 | 27 | 0.230 |
Why?
| Tularemia | 2 | 2006 | 21 | 0.230 |
Why?
| Fatal Outcome | 3 | 2017 | 195 | 0.230 |
Why?
| Middle Aged | 24 | 2014 | 12069 | 0.220 |
Why?
| Macrophages | 3 | 1994 | 363 | 0.200 |
Why?
| Ketoconazole | 7 | 1997 | 17 | 0.200 |
Why?
| Diagnosis, Differential | 4 | 2014 | 1037 | 0.190 |
Why?
| Arkansas | 4 | 2020 | 1977 | 0.190 |
Why?
| Mycobacterium Infections, Nontuberculous | 1 | 2020 | 20 | 0.180 |
Why?
| Neoplasms | 2 | 2020 | 1235 | 0.180 |
Why?
| Adult | 30 | 2010 | 13236 | 0.180 |
Why?
| Sepsis | 3 | 2020 | 220 | 0.180 |
Why?
| Bacteremia | 2 | 2004 | 90 | 0.170 |
Why?
| Conjunctivitis, Bacterial | 1 | 1999 | 4 | 0.170 |
Why?
| Staphylococcus aureus | 4 | 2007 | 326 | 0.170 |
Why?
| AIDS-Related Opportunistic Infections | 2 | 1996 | 40 | 0.150 |
Why?
| Antibodies, Fungal | 2 | 1995 | 4 | 0.150 |
Why?
| Thoracic Vertebrae | 1 | 1998 | 36 | 0.150 |
Why?
| Abscess | 1 | 1998 | 41 | 0.150 |
Why?
| Treatment Outcome | 9 | 2014 | 5141 | 0.150 |
Why?
| Quinine | 1 | 2017 | 5 | 0.150 |
Why?
| Babesia | 1 | 2017 | 5 | 0.150 |
Why?
| Clindamycin | 1 | 2017 | 13 | 0.150 |
Why?
| Platelet Transfusion | 1 | 2017 | 28 | 0.150 |
Why?
| Female | 31 | 2012 | 26472 | 0.150 |
Why?
| Haemophilus Infections | 2 | 1994 | 7 | 0.140 |
Why?
| Lumbar Vertebrae | 1 | 1998 | 98 | 0.140 |
Why?
| Haemophilus influenzae | 2 | 1994 | 19 | 0.140 |
Why?
| Sensitivity and Specificity | 4 | 2011 | 861 | 0.140 |
Why?
| Aged, 80 and over | 6 | 2017 | 3129 | 0.140 |
Why?
| Pulmonary Alveoli | 2 | 1987 | 19 | 0.140 |
Why?
| Cross Reactions | 3 | 2011 | 42 | 0.140 |
Why?
| Methicillin Resistance | 2 | 2007 | 17 | 0.140 |
Why?
| Immunoenzyme Techniques | 3 | 2011 | 143 | 0.140 |
Why?
| Itraconazole | 6 | 1997 | 40 | 0.130 |
Why?
| Disease Outbreaks | 4 | 1992 | 125 | 0.130 |
Why?
| Lymphocytes | 4 | 1985 | 152 | 0.130 |
Why?
| Imipenem | 1 | 1995 | 10 | 0.130 |
Why?
| Immunocompromised Host | 3 | 2020 | 119 | 0.130 |
Why?
| Fluconazole | 3 | 2003 | 34 | 0.120 |
Why?
| Orchitis | 1 | 1994 | 3 | 0.120 |
Why?
| Epididymitis | 1 | 1994 | 5 | 0.120 |
Why?
| Radiography | 2 | 2010 | 489 | 0.120 |
Why?
| Aged | 16 | 2007 | 9310 | 0.110 |
Why?
| Lymphocyte Activation | 6 | 1990 | 172 | 0.110 |
Why?
| Diagnostic Errors | 1 | 2014 | 63 | 0.110 |
Why?
| Remission Induction | 1 | 2014 | 207 | 0.110 |
Why?
| Candidiasis | 2 | 2003 | 114 | 0.110 |
Why?
| Francisella tularensis | 2 | 2006 | 15 | 0.110 |
Why?
| Gentamicins | 2 | 2006 | 31 | 0.110 |
Why?
| United States | 5 | 2017 | 4860 | 0.110 |
Why?
| Coccidioidomycosis | 1 | 2012 | 6 | 0.100 |
Why?
| Otitis Media, Suppurative | 1 | 1992 | 9 | 0.100 |
Why?
| Cryptococcosis | 2 | 1989 | 20 | 0.100 |
Why?
| Predictive Value of Tests | 1 | 2014 | 903 | 0.090 |
Why?
| Ceftriaxone | 2 | 1988 | 26 | 0.090 |
Why?
| Tomography | 1 | 2010 | 4 | 0.090 |
Why?
| Anti-Bacterial Agents | 2 | 2007 | 744 | 0.090 |
Why?
| North America | 1 | 2010 | 64 | 0.090 |
Why?
| Head | 1 | 2010 | 73 | 0.090 |
Why?
| Focal Infection | 1 | 1989 | 1 | 0.080 |
Why?
| Meningoencephalitis | 1 | 1989 | 6 | 0.080 |
Why?
| Adolescent | 7 | 2010 | 6356 | 0.080 |
Why?
| Pseudomonas Infections | 2 | 2004 | 48 | 0.080 |
Why?
| Disease Reservoirs | 2 | 1987 | 4 | 0.080 |
Why?
| Pseudomonas aeruginosa | 2 | 2004 | 72 | 0.080 |
Why?
| Ischemic Attack, Transient | 1 | 1989 | 56 | 0.080 |
Why?
| Rodentia | 2 | 1987 | 18 | 0.080 |
Why?
| Fungemia | 2 | 2011 | 37 | 0.080 |
Why?
| Debridement | 1 | 2008 | 46 | 0.080 |
Why?
| Fresh Water | 1 | 1987 | 7 | 0.080 |
Why?
| Meningitis, Haemophilus | 1 | 1988 | 8 | 0.080 |
Why?
| Candida | 2 | 2003 | 60 | 0.070 |
Why?
| Water | 1 | 1987 | 77 | 0.070 |
Why?
| Soft Tissue Infections | 1 | 2007 | 8 | 0.070 |
Why?
| Staphylococcal Skin Infections | 1 | 2007 | 4 | 0.070 |
Why?
| Community-Acquired Infections | 1 | 2007 | 39 | 0.070 |
Why?
| Practice Guidelines as Topic | 1 | 2010 | 449 | 0.070 |
Why?
| Peritonitis, Tuberculous | 1 | 1986 | 1 | 0.070 |
Why?
| Staphylococcal Infections | 3 | 2007 | 268 | 0.070 |
Why?
| Phagocytosis | 4 | 1994 | 48 | 0.070 |
Why?
| Optic Neuritis | 1 | 2006 | 21 | 0.070 |
Why?
| Immunity, Cellular | 4 | 1994 | 69 | 0.070 |
Why?
| Salvage Therapy | 1 | 2006 | 139 | 0.070 |
Why?
| Triazoles | 1 | 2006 | 108 | 0.070 |
Why?
| Drug Therapy, Combination | 3 | 2005 | 377 | 0.060 |
Why?
| Tetracyclines | 1 | 2005 | 7 | 0.060 |
Why?
| Blood | 1 | 1985 | 28 | 0.060 |
Why?
| Recurrence | 3 | 1997 | 652 | 0.060 |
Why?
| Cefotaxime | 1 | 1984 | 4 | 0.060 |
Why?
| Skin Diseases, Infectious | 1 | 1984 | 8 | 0.060 |
Why?
| Leukocytes | 1 | 1984 | 66 | 0.060 |
Why?
| Health Facility Closure | 1 | 2004 | 3 | 0.060 |
Why?
| DNA Fingerprinting | 1 | 2004 | 62 | 0.060 |
Why?
| Bacterial Infections | 1 | 1984 | 95 | 0.060 |
Why?
| Endocarditis | 2 | 1982 | 32 | 0.060 |
Why?
| Microbial Sensitivity Tests | 3 | 2007 | 269 | 0.060 |
Why?
| Trismus | 1 | 1983 | 3 | 0.060 |
Why?
| Tetanus | 1 | 1983 | 3 | 0.060 |
Why?
| Infection Control | 1 | 2004 | 50 | 0.060 |
Why?
| Magnetic Resonance Imaging | 2 | 2010 | 1537 | 0.060 |
Why?
| Endocarditis, Bacterial | 1 | 1984 | 44 | 0.060 |
Why?
| Pneumonia | 3 | 1991 | 118 | 0.060 |
Why?
| Onygenales | 1 | 2003 | 1 | 0.060 |
Why?
| Male Urogenital Diseases | 1 | 2003 | 2 | 0.060 |
Why?
| Female Urogenital Diseases | 1 | 2003 | 5 | 0.060 |
Why?
| Streptococcal Infections | 1 | 1984 | 46 | 0.060 |
Why?
| T-Lymphocytes | 1 | 1985 | 338 | 0.050 |
Why?
| Cross Infection | 1 | 2004 | 95 | 0.050 |
Why?
| Intensive Care Units, Neonatal | 1 | 2004 | 115 | 0.050 |
Why?
| Brain Abscess | 1 | 1982 | 12 | 0.050 |
Why?
| Phagocytes | 1 | 1982 | 12 | 0.050 |
Why?
| Nocardia Infections | 1 | 1982 | 5 | 0.050 |
Why?
| Aortic Valve | 1 | 1984 | 113 | 0.050 |
Why?
| Clinical Protocols | 1 | 2003 | 108 | 0.050 |
Why?
| Animals | 6 | 2010 | 13187 | 0.050 |
Why?
| Therapeutic Irrigation | 3 | 1987 | 30 | 0.050 |
Why?
| Cephalosporins | 1 | 1982 | 41 | 0.050 |
Why?
| Retrospective Studies | 3 | 2010 | 6108 | 0.050 |
Why?
| Skin Diseases | 1 | 2003 | 112 | 0.050 |
Why?
| Bone Diseases | 1 | 2003 | 99 | 0.050 |
Why?
| Drug Administration Schedule | 3 | 2007 | 376 | 0.050 |
Why?
| Neutrophils | 2 | 1994 | 145 | 0.050 |
Why?
| Nontuberculous Mycobacteria | 1 | 2020 | 12 | 0.050 |
Why?
| Young Adult | 1 | 2010 | 3958 | 0.050 |
Why?
| Opportunistic Infections | 2 | 2000 | 58 | 0.040 |
Why?
| Outpatients | 1 | 2020 | 113 | 0.040 |
Why?
| Consensus | 1 | 2020 | 148 | 0.040 |
Why?
| Dose-Response Relationship, Drug | 2 | 2007 | 1376 | 0.040 |
Why?
| Corneal Edema | 1 | 1999 | 4 | 0.040 |
Why?
| Anterior Chamber | 1 | 1999 | 8 | 0.040 |
Why?
| Ophthalmic Solutions | 1 | 1999 | 18 | 0.040 |
Why?
| Conjunctiva | 1 | 1999 | 13 | 0.040 |
Why?
| Antibodies, Bacterial | 1 | 1999 | 28 | 0.040 |
Why?
| Tomography Scanners, X-Ray Computed | 1 | 1998 | 12 | 0.040 |
Why?
| Spinal Diseases | 1 | 1998 | 21 | 0.040 |
Why?
| Spine | 1 | 1998 | 94 | 0.040 |
Why?
| Soil Microbiology | 2 | 1987 | 18 | 0.040 |
Why?
| Biopsy | 1 | 1999 | 584 | 0.030 |
Why?
| Child | 6 | 1993 | 6847 | 0.030 |
Why?
| Multicenter Studies as Topic | 1 | 1995 | 84 | 0.030 |
Why?
| Iron-Dextran Complex | 1 | 1994 | 3 | 0.030 |
Why?
| Serotyping | 1 | 1994 | 12 | 0.030 |
Why?
| Breast Diseases | 1 | 1995 | 26 | 0.030 |
Why?
| Breast | 1 | 1995 | 85 | 0.030 |
Why?
| Monocytes | 2 | 1985 | 131 | 0.030 |
Why?
| Anaphylaxis | 1 | 1994 | 71 | 0.030 |
Why?
| Cytotoxicity, Immunologic | 1 | 1994 | 54 | 0.030 |
Why?
| Catheterization | 2 | 2003 | 96 | 0.030 |
Why?
| Macrophages, Alveolar | 1 | 1994 | 28 | 0.030 |
Why?
| Desensitization, Immunologic | 1 | 1994 | 107 | 0.030 |
Why?
| Time Factors | 3 | 1985 | 2903 | 0.030 |
Why?
| Ecology | 2 | 1990 | 17 | 0.030 |
Why?
| Urine | 1 | 2011 | 23 | 0.030 |
Why?
| Acridine Orange | 1 | 1991 | 2 | 0.030 |
Why?
| Phenazines | 1 | 1991 | 2 | 0.030 |
Why?
| Gentian Violet | 1 | 1991 | 4 | 0.030 |
Why?
| Serum | 1 | 2011 | 32 | 0.020 |
Why?
| Staining and Labeling | 1 | 1991 | 97 | 0.020 |
Why?
| Risk Assessment | 2 | 2007 | 1259 | 0.020 |
Why?
| Trees | 1 | 1990 | 18 | 0.020 |
Why?
| Diet, Reducing | 1 | 1990 | 36 | 0.020 |
Why?
| Occupational Diseases | 1 | 1990 | 89 | 0.020 |
Why?
| Flucytosine | 1 | 1989 | 14 | 0.020 |
Why?
| Lung Diseases | 2 | 2000 | 92 | 0.020 |
Why?
| Cost-Benefit Analysis | 2 | 2000 | 274 | 0.020 |
Why?
| Tomography, X-Ray Computed | 2 | 1992 | 1159 | 0.020 |
Why?
| Wisconsin | 4 | 1990 | 45 | 0.020 |
Why?
| Sinusitis | 1 | 1988 | 50 | 0.020 |
Why?
| Obesity | 2 | 1990 | 1113 | 0.020 |
Why?
| Lung | 2 | 1991 | 486 | 0.020 |
Why?
| Bronchi | 1 | 1987 | 43 | 0.020 |
Why?
| Meningitis, Fungal | 1 | 2006 | 1 | 0.020 |
Why?
| Ethmoid Sinusitis | 1 | 2006 | 2 | 0.020 |
Why?
| Probability | 1 | 2007 | 164 | 0.020 |
Why?
| Statistics, Nonparametric | 1 | 2007 | 194 | 0.020 |
Why?
| Maxillary Sinusitis | 1 | 2006 | 11 | 0.020 |
Why?
| Echinococcosis | 1 | 1986 | 3 | 0.020 |
Why?
| Swine Diseases | 1 | 1986 | 7 | 0.020 |
Why?
| Zoonoses | 1 | 1986 | 13 | 0.020 |
Why?
| Cerebrospinal Fluid | 1 | 2006 | 32 | 0.020 |
Why?
| Endocrine System Diseases | 1 | 1985 | 10 | 0.020 |
Why?
| Antitubercular Agents | 1 | 1986 | 106 | 0.020 |
Why?
| Leukocyte Count | 1 | 1985 | 70 | 0.020 |
Why?
| Breast Neoplasms | 1 | 1995 | 1174 | 0.020 |
Why?
| Nausea | 1 | 1985 | 50 | 0.020 |
Why?
| T-Lymphocytes, Helper-Inducer | 1 | 1985 | 42 | 0.020 |
Why?
| Follow-Up Studies | 2 | 2007 | 2182 | 0.020 |
Why?
| T-Lymphocytes, Regulatory | 1 | 1985 | 86 | 0.020 |
Why?
| Thymidine | 1 | 1984 | 18 | 0.020 |
Why?
| Cefazolin | 1 | 1984 | 12 | 0.020 |
Why?
| Drug Resistance, Microbial | 1 | 1984 | 46 | 0.020 |
Why?
| Mycobacterium tuberculosis | 1 | 1986 | 285 | 0.010 |
Why?
| Mitogens | 1 | 1984 | 9 | 0.010 |
Why?
| Blood-Borne Pathogens | 1 | 2004 | 7 | 0.010 |
Why?
| Logistic Models | 1 | 2007 | 888 | 0.010 |
Why?
| Thumb | 1 | 1983 | 6 | 0.010 |
Why?
| Severity of Illness Index | 1 | 2007 | 945 | 0.010 |
Why?
| Infant, Low Birth Weight | 1 | 2004 | 62 | 0.010 |
Why?
| Heart Septal Defects, Ventricular | 1 | 1984 | 43 | 0.010 |
Why?
| Heart Valve Diseases | 1 | 1984 | 47 | 0.010 |
Why?
| Infusions, Parenteral | 1 | 1982 | 11 | 0.010 |
Why?
| Biopsy, Needle | 2 | 1995 | 183 | 0.010 |
Why?
| Bacteria | 1 | 1984 | 224 | 0.010 |
Why?
| Cohort Studies | 1 | 2007 | 1422 | 0.010 |
Why?
| Polymerase Chain Reaction | 1 | 2004 | 453 | 0.010 |
Why?
| Pregnancy | 2 | 2000 | 2607 | 0.010 |
Why?
| Neutropenia | 1 | 2003 | 116 | 0.010 |
Why?
| Leukemia, Lymphoid | 1 | 1982 | 6 | 0.010 |
Why?
| Cellulitis | 1 | 1981 | 12 | 0.010 |
Why?
| Cell Migration Inhibition | 1 | 1981 | 2 | 0.010 |
Why?
| Phytohemagglutinins | 1 | 1981 | 9 | 0.010 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 1982 | 60 | 0.010 |
Why?
| Candida albicans | 1 | 1981 | 31 | 0.010 |
Why?
| Decision Making | 1 | 2004 | 265 | 0.010 |
Why?
| Prospective Studies | 3 | 1995 | 2364 | 0.010 |
Why?
| Double-Blind Method | 1 | 2003 | 681 | 0.010 |
Why?
| Survival Rate | 1 | 2004 | 894 | 0.010 |
Why?
| Imidazoles | 1 | 1982 | 119 | 0.010 |
Why?
| Piperazines | 1 | 1982 | 117 | 0.010 |
Why?
| Disseminated Intravascular Coagulation | 1 | 1980 | 7 | 0.010 |
Why?
| Mediastinitis | 1 | 2000 | 3 | 0.010 |
Why?
| Health Planning Guidelines | 1 | 2000 | 13 | 0.010 |
Why?
| Arthritis | 1 | 2000 | 42 | 0.010 |
Why?
| Pericarditis | 1 | 2000 | 20 | 0.010 |
Why?
| Central Nervous System Diseases | 1 | 2000 | 27 | 0.010 |
Why?
| Jejunum | 1 | 1980 | 54 | 0.010 |
Why?
| Ileum | 1 | 1980 | 89 | 0.010 |
Why?
| Kidney Transplantation | 1 | 1981 | 175 | 0.010 |
Why?
| Infant | 1 | 1988 | 3567 | 0.010 |
Why?
| Pregnancy Complications, Infectious | 1 | 2000 | 73 | 0.010 |
Why?
| Prognosis | 1 | 1983 | 1942 | 0.010 |
Why?
| Treatment Failure | 1 | 1997 | 114 | 0.010 |
Why?
| Postoperative Complications | 2 | 1981 | 984 | 0.010 |
Why?
| Infant, Newborn | 1 | 2004 | 2772 | 0.010 |
Why?
| Pregnancy Complications | 1 | 2000 | 382 | 0.010 |
Why?
| Heart Failure | 1 | 1980 | 458 | 0.010 |
Why?
| Anemia, Iron-Deficiency | 1 | 1994 | 19 | 0.010 |
Why?
| Pilot Projects | 1 | 1995 | 699 | 0.010 |
Why?
| Evaluation Studies as Topic | 1 | 1991 | 107 | 0.010 |
Why?
| Bacteriological Techniques | 1 | 1991 | 41 | 0.010 |
Why?
| Rats, Inbred Strains | 1 | 1991 | 196 | 0.010 |
Why?
| Minnesota | 1 | 1990 | 24 | 0.010 |
Why?
| Ketosis | 1 | 1990 | 3 | 0.010 |
Why?
| Chemotaxis | 1 | 1990 | 23 | 0.010 |
Why?
| Antimycin A | 1 | 1990 | 5 | 0.010 |
Why?
| Fasting | 1 | 1990 | 70 | 0.010 |
Why?
| Skin Tests | 1 | 1990 | 58 | 0.010 |
Why?
| Regression Analysis | 1 | 1990 | 395 | 0.010 |
Why?
| Mucormycosis | 1 | 1988 | 29 | 0.010 |
Why?
| Acute Disease | 1 | 1990 | 366 | 0.010 |
Why?
| Body Weight | 1 | 1990 | 513 | 0.000 |
Why?
| Aspergillosis | 1 | 1988 | 125 | 0.000 |
Why?
| Blood Glucose | 1 | 1990 | 439 | 0.000 |
Why?
| Incidence | 1 | 1990 | 1003 | 0.000 |
Why?
| Immunodiffusion | 1 | 1987 | 3 | 0.000 |
Why?
| Complement Fixation Tests | 1 | 1987 | 3 | 0.000 |
Why?
| Corynebacterium Infections | 1 | 1986 | 1 | 0.000 |
Why?
| Fiber Optic Technology | 1 | 1986 | 16 | 0.000 |
Why?
| Weather | 1 | 1986 | 4 | 0.000 |
Why?
| Camping | 1 | 1986 | 3 | 0.000 |
Why?
| Epidemiologic Methods | 1 | 1986 | 49 | 0.000 |
Why?
| Dogs | 1 | 1986 | 182 | 0.000 |
Why?
| Rats | 1 | 1991 | 3305 | 0.000 |
Why?
| Swine | 1 | 1986 | 393 | 0.000 |
Why?
| Rural Population | 1 | 1986 | 540 | 0.000 |
Why?
| Prednisolone | 1 | 1981 | 55 | 0.000 |
Why?
| Mediastinal Diseases | 1 | 1980 | 8 | 0.000 |
Why?
| Risk | 1 | 1980 | 320 | 0.000 |
Why?
| Tuberculosis | 1 | 1980 | 146 | 0.000 |
Why?
| Sex Factors | 1 | 1980 | 691 | 0.000 |
Why?
|
|
Bradsher's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|